206 related articles for article (PubMed ID: 8521296)
41. Thalidomide: focus on its employment in rheumatologic diseases.
Ossandon A; Cassarà EA; Priori R; Valesini G
Clin Exp Rheumatol; 2002; 20(5):709-18. PubMed ID: 12412207
[TBL] [Abstract][Full Text] [Related]
42. Hydrolysis of thalidomide abrogates its ability to enhance mononuclear cell synthesis of IL-2 as well as its ability to suppress the synthesis of TNF-alpha.
Shannon EJ; Sandoval F; Krahenbuhl JL
Immunopharmacology; 1997 Apr; 36(1):9-15. PubMed ID: 9129992
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.
Stommel EW; Cohen JA; Fadul CE; Cogbill CH; Graber DJ; Kingman L; Mackenzie T; Channon Smith JY; Harris BT
Amyotroph Lateral Scler; 2009; 10(5-6):393-404. PubMed ID: 19922130
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.
Facchini S; Candusso M; Martelossi S; Liubich M; Panfili E; Ventura A
J Pediatr Gastroenterol Nutr; 2001 Feb; 32(2):178-81. PubMed ID: 11321389
[TBL] [Abstract][Full Text] [Related]
45. Depressed interleukin-12 production by peripheral blood mononuclear cells after in vitro stimulation with the 30-kDa antigen in recurrent pulmonary tuberculosis patients.
Lee JS; Song CH; Kim CH; Kong SJ; Shon MH; Suhr JW; Jung SS; Lim JH; Kim HJ; Park JK; Paik TH; Jo EK
Med Microbiol Immunol; 2003 May; 192(2):61-9. PubMed ID: 12736818
[TBL] [Abstract][Full Text] [Related]
46. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA
N Engl J Med; 1997 May; 336(21):1487-93. PubMed ID: 9154767
[TBL] [Abstract][Full Text] [Related]
47. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production.
Andrade RM; Lima PG; Filho RG; Hygino J; Milczanowski SF; Andrade AF; Lauria C; Brindeiro R; Tanuri A; Bento CA
AIDS; 2007 Aug; 21(13):1763-70. PubMed ID: 17690575
[TBL] [Abstract][Full Text] [Related]
49. Amelioration of experimental colitis by thalidomide.
Kenet G; Wardi J; Avni Y; Aeed H; Shirin H; Zaidel L; Hershkoviz R; Bruck R
Isr Med Assoc J; 2001 Sep; 3(9):644-8. PubMed ID: 11574978
[TBL] [Abstract][Full Text] [Related]
50. Specific cytokine patterns of pulmonary tuberculosis in Central Africa.
Nemeth J; Winkler HM; Boeck L; Adegnika AA; Clement E; Mve TM; Kremsner PG; Winkler S
Clin Immunol; 2011 Jan; 138(1):50-9. PubMed ID: 20951096
[TBL] [Abstract][Full Text] [Related]
51. Differential induction of apoptosis and necrosis in monocytes from patients with tuberculosis and healthy control subjects.
Gil DP; León LG; Correa LI; Maya JR; París SC; García LF; Rojas M
J Infect Dis; 2004 Jun; 189(11):2120-8. PubMed ID: 15143481
[TBL] [Abstract][Full Text] [Related]
52. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production.
Marriott JB; Westby M; Cookson S; Guckian M; Goodbourn S; Muller G; Shire MG; Stirling D; Dalgleish AG
J Immunol; 1998 Oct; 161(8):4236-43. PubMed ID: 9780198
[TBL] [Abstract][Full Text] [Related]
53. Immunological consequences of thalidomide treatment in Sjögren's syndrome.
Moutsopoulos NM; Angelov N; Sankar V; Leakan RA; Pillemer S; Wahl SM
Ann Rheum Dis; 2006 Jan; 65(1):112-4. PubMed ID: 16344495
[TBL] [Abstract][Full Text] [Related]
54. Thalidomide modulates Mycobacterium leprae-induced NF-κB pathway and lower cytokine response.
Hernandez Mde O; Fulco Tde O; Pinheiro RO; Pereira Rde M; Redner P; Sarno EN; Lopes UG; Sampaio EP
Eur J Pharmacol; 2011 Nov; 670(1):272-9. PubMed ID: 21925494
[TBL] [Abstract][Full Text] [Related]
55. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
Sampaio EP; Sarno EN; Galilly R; Cohn ZA; Kaplan G
J Exp Med; 1991 Mar; 173(3):699-703. PubMed ID: 1997652
[TBL] [Abstract][Full Text] [Related]
56. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
57. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.
Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J
Lancet; 1998 Nov; 352(9140):1586-9. PubMed ID: 9843104
[TBL] [Abstract][Full Text] [Related]
58. Liposomal Glutathione Supplementation Restores TH1 Cytokine Response to Mycobacterium tuberculosis Infection in HIV-Infected Individuals.
Ly J; Lagman M; Saing T; Singh MK; Tudela EV; Morris D; Anderson J; Daliva J; Ochoa C; Patel N; Pearce D; Venketaraman V
J Interferon Cytokine Res; 2015 Nov; 35(11):875-87. PubMed ID: 26133750
[TBL] [Abstract][Full Text] [Related]
59. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
Saliu OY; Sofer C; Stein DS; Schwander SK; Wallis RS
J Infect Dis; 2006 Aug; 194(4):486-92. PubMed ID: 16845632
[TBL] [Abstract][Full Text] [Related]
60. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A
Haematologica; 2004 May; 89(5):552-6. PubMed ID: 15136218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
